Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - pubmed.ncbi.nlm.nih.gov
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - europepmc.org
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah… - 2020 - ir.ymlib.yonsei.ac.kr
Background: Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez…�- The lancet�…, 2020 - mdanderson.elsevierpure.com
Background: Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - s-space.snu.ac.kr
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez…�- The Lancet�…, 2020 - mayoclinic.elsevierpure.com
Background: Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - Elsevier
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - hero.epa.gov
BACKGROUND: Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - snucm.elsevierpure.com
Background: Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…